<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02379572</url>
  </required_header>
  <id_info>
    <org_study_id>Nch1</org_study_id>
    <nct_id>NCT02379572</nct_id>
  </id_info>
  <brief_title>Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas</brief_title>
  <official_title>Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas - A Prospective Multicenter Parallel Group Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard treatment of glioblastomas (GBMs) consists of microsurgical resection followed by
      concomitant chemoradiation. The extent of resection is one of the most important prognostic
      factors with significant influence on the survival of patients. State of the art technique to
      achieve the most radical resection possible in conventional surgery is fluorescence-guidance
      with 5-aminolevulinic acid (5-ALA). If available, intraoperative MRI (iMRI)-guided tumor
      resection enables an intraoperative resection control and subsequent continuation of surgery
      if contrast enhancing tumor remnants are found. Therefore a more radical resection and longer
      survival of patients might be possible. To date no comparison of these two leading
      technologies for GBM-surgery is available to identify the best surgical therapy of this fatal
      disease and to justify significant healthcare-economic differences between both technologies.

      Goal of this study is to assess the value of iMRI guidance in the resection of GBMs in
      comparison to conventional 5-ALA microsurgery. Primary endpoint is the number of total
      resections (no residual contrast enhancement) in the postoperative MRI (T1+CM within 48 hours
      after surgery) in each group. Secondary endpoints are perioperative clinical data,
      progression free survival, patients' clinical condition and overall survival.

      The study design was chosen to be a parallel-group approach to compare iMRI and 5-ALA centers
      (n=13) to exclude possible bias which might be found by randomizing patients within
      individual iMRI centers and to have surgeons with the most experience possible in use of each
      respective technology.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete resections in the postoperative MRI (T1+/-CM) within 48 hours after surgery</measure>
    <time_frame>48 hour</time_frame>
    <description>Completeness of resection in the postoperative MRI within 48h after surgery. Blinded analysis by an independent radiologist.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients' clinical condition (KPS)</measure>
    <time_frame>preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery</time_frame>
    <description>-KPS clinical scoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' clinical condition (NIHSS)</measure>
    <time_frame>preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery</time_frame>
    <description>-NIHSS stroke score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' clinical condition (QoL)</measure>
    <time_frame>preoperative (day before surgery), 1 week, 3Months, 6Months, 9Months, 12Months after surgery</time_frame>
    <description>-quality of life (EORTC) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital stay after surgery</measure>
    <time_frame>Time of hospital stay (average 7days)</time_frame>
    <description>-ICU and overall hospital stay after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' adjuvant treatment</measure>
    <time_frame>3Months, 6Months, 9Months, 12Months after surgery</time_frame>
    <description>-adjuvant treatment each patient has received</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent tumor growth (RANO criteria)</measure>
    <time_frame>3Months, 6Months, 9Months, 12Months after surgery</time_frame>
    <description>-recurrent tumor growth (RANO criteria) according to local tumor boards and independent blinded analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up imaging</measure>
    <time_frame>3Months, 6Months, 9Months, 12Months after surgery</time_frame>
    <description>-follow-up imaging 3, 6, 9, 12 months postoperative incl. independent blinded analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histology</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>Histological analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MGMT (O6-methylguanine-DNA-methyltransferase) analysis</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>MGMT promoter analysis (Routine molecular diagnostics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IDH-1 (isocitrate dehydrogenase) analysis</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>IDH-1 mutation analysis (Routine molecular diagnostics)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Day of surgery - 6 months - 12 months</time_frame>
    <description>6M&amp;12M-PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Day of surgery - Death of patient (Max. 10 years follow-up)</time_frame>
    <description>OS of patients</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Preoperative tumor localization and resectability concerning eloquent regions</measure>
    <time_frame>Blinded analysis of preoperative imaging (not older than 3 days prior to surgery)</time_frame>
    <description>Independent blinded analysis of the preoperative imaging data by a blinded neurosurgeon with extensive experience in the resection of gliomas. Analysis will be done before the final evaluation of results. (Within 12 months)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>iMRI-guided surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Resection of Glioblastomas with iMRI-guidance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-ALA-guided surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Resection of Glioblastomas with 5-ALA-fluorescence-guidance</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iMRI-guided surgery</intervention_name>
    <description>For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.</description>
    <arm_group_label>iMRI-guided surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-ALA-guided surgery</intervention_name>
    <description>For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.</description>
    <arm_group_label>5-ALA-guided surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In MRI suspected primary singular untreated GBM

          2. Planned total resection of the tumor according to the surgeon

          3. Patient ≥18 years, ≤80 years

          4. Preoperative KPS ≥ 60%, American Society of Anesthesiologists (ASA) score 1 and 2

          5. Patients' informed consent

        Exclusion Criteria:

          1. Tumors of the midline, basal ganglia, cerebellum, brain stem, eloquent areas

          2. Multifocal glioblastoma

          3. Substantial (&gt;50%), non-contrast enhancing tumor areas suggesting low-grade glioma
             with malignant transformation

          4. Contraindications to MRI

          5. Inability to give consent because of language barrier or dysphasia

          6. Histological diagnosis other than Glioblastoma multiforme WHO °IV

          7. Increased risk of thrombosis (e.g. Factor V Leiden)

          8. Pregnancy or breast feeding

          9. Hypersensibility for 5-ALA oder porphyrins

         10. Acute or chronic Porphyria

         11. Renal insufficiency

         12. Hepatic insufficiency

         13. High likelihood of inability to receive adjuvant therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constantin Roder, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen, Department of Neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Constantin Roder, Dr.</last_name>
    <phone>+4970712980325</phone>
    <email>constantin.roder@uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manola Zago, Dr.</last_name>
    <phone>+49 7071 29 85629</phone>
    <email>manola.zago@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurosurgery, Universitätsklinikum Bonn, Bonn, Germany</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hartmut Vatter</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, Universität zu Köln, Köln, Germany</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Goldbrunner, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Dresden Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Stockhammer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, Heinrich-Heine-Universität Düsseldorf, Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sabel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, Friedrich-Alexander-University Erlangen-Nürnberg</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Merkel, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, Johann Wolfgang Goethe-University Frankfurt am Main</name>
      <address>
        <city>Frankfurt a.M.</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Senft, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, Georg-August-Universität Göttingen, Göttingen,</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Stockhammer, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, University of Ulm, Hospital Günzburg,</name>
      <address>
        <city>Günzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Coburger, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Hamburg, Klinik für Neurochirurgie</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Kremer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>International Neuroscience Institute Hannover, Hannover, Germany</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Giordano, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, Ruprecht-Karls-University Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moritz Scherer, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, University of Schleswig-Holstein, Kiel, Germany</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Schwartz, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, Westfälische Wilhelms-Universität Münster, Münster, Germany</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Stummer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, Eberhard Karls University, Tübingen,</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Constantin Roder, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, Julius-Maximilians-Universität Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Löhr, PD Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>5-ALA</keyword>
  <keyword>Intraoperative MRI</keyword>
  <keyword>Extent of resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

